ZyVersa Therapeutics, Inc. (ZVSA): Nasdaq/NYSE listing notice — Zyversa receives Nasdaq delisting notice for low bid price; will appeal

ZyVersa Therapeutics, Inc.

Received Nasdaq letter on May 27, 2025 for non-compliance with $1.00 minimum bid price rule.
Ineligible for cure period due to two reverse stock splits in past two years (1:35 Dec 2023, 1:10 Apr 2024).
Unless appeal requested by June 3, 2025, securities face delisting on June 5, 2025.
Company intends to appeal and request hearing, which will stay delisting pending panel decision.
No assurance of regaining compliance with continued listing requirements.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 27, 2025, Zyversa Therapeutics, Inc. (the “Company”) received a letter (the “Minimum Bid Price Deficiency Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Capital Market Stock Exchange (“Nasdaq”) notifying the Company that because the Company’s common stock had a closing bid price of less than $1.00 for 30 consecutive business days immediately preceding the Minimum Bid Price Deficiency Letter, the Company is not in compliance with Listing Rule 5550(a)(2) (the “Rule”). Typically, a company would be afforded a 180-calendar day period to demonstrate compliance w

View on SEC.gov

3 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-013038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.